Haemonetics Corporation
HAE
$57.17
$0.280.49%
NYSE
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.37B | 1.36B | 1.33B | 1.31B | 1.27B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.37B | 1.36B | 1.33B | 1.31B | 1.27B |
| Cost of Revenue | 608.93M | 611.62M | 604.92M | 597.14M | 582.96M |
| Gross Profit | 764.59M | 749.61M | 728.97M | 711.92M | 687.22M |
| SG&A Expenses | 413.13M | 413.49M | 416.84M | 418.96M | 403.29M |
| Depreciation & Amortization | 47.39M | 42.07M | 37.03M | 32.03M | 29.58M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.13B | 1.13B | 1.11B | 1.10B | 1.07B |
| Operating Income | 243.27M | 236.15M | 221.08M | 208.70M | 201.52M |
| Income Before Tax | 164.75M | 158.86M | 146.99M | 151.87M | 161.08M |
| Income Tax Expenses | 34.68M | 35.05M | 32.10M | 34.31M | 34.50M |
| Earnings from Continuing Operations | 130.07 | 123.81 | 114.89 | 117.56 | 126.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 130.07M | 123.81M | 114.89M | 117.56M | 126.57M |
| EBIT | 243.27M | 236.15M | 221.08M | 208.70M | 201.52M |
| EBITDA | 349.68M | 337.07M | 315.94M | 297.31M | 286.45M |
| EPS Basic | 2.56 | 2.43 | 2.26 | 2.32 | 2.50 |
| Normalized Basic EPS | 2.80 | 2.80 | 2.67 | 2.41 | 2.38 |
| EPS Diluted | 2.54 | 2.41 | 2.23 | 2.29 | 2.46 |
| Normalized Diluted EPS | 2.78 | 2.77 | 2.64 | 2.38 | 2.34 |
| Average Basic Shares Outstanding | 202.91M | 203.40M | 203.23M | 202.82M | 202.48M |
| Average Diluted Shares Outstanding | 204.85M | 205.66M | 205.81M | 205.59M | 205.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |